Trisubstituted 1,3,5-triazine derivatives
This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0, 1, 2, 3 or 4; R1 and R2 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl; and each R4 independently is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is &#8212;X&#8212;R5 or &#8212;X&#8212;Alk&#8212;R6; wherein R5 and R6 each independently are indanyl, indolyl or phenyl; each of said indanyl, indolyl or phenyl may be substituted; and X is &#8212;NR3&#8212;, &#8212;NH&#8212;NH&#8212;, &#8212;N&boxH;N&#8212;, &#8212;O&#8212;, &#8212;S &#8212;, &#8212;S(&boxH;O)&#8212; or &#8212;S(&boxH;O)2&#8212;; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and pharmaceutical compositions comprising them.
Janssen Pharmaceutica N.V.
C C C A C C C
C07D C07D C07D A61P C07D C07D C07D
inventional inventional inventional inventional inventional inventional inventional
Robert W. Bart Paul Adriaan Jan Michael Joseph Jan Marc René Chih Yung Donald William Lucien Maria Henricus Frederik Frans Desiré
Kavash De Corte Janssen Kukla Heeres De Jonge Ho Ludovici Koymans Daeyaert